Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03242278 · ClinicalTrials.gov registry record
Real-world Dosing Patterns of Rivaroxaban in the United States
A clinical trial of Atrial Fibrillation, sponsored by Bayer.
- Completed
- Registry status
- 12,507
- Enrollment target
- 1
- Study location
NCT03242278: Completed study of Atrial Fibrillation, sponsored by Bayer.
NCT03242278 is a study of Atrial Fibrillation that has completed, run by Bayer. The registered enrollment target is 12,507 participants, above the 2,935-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (326% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03242278, a study of Atrial Fibrillation, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 12,507 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to assess the proportion of Non-valvular atrial fibrillation (NVAF) patients receiving the standard dose of 20 mg of rivaroxaban or the reduced dose of 15 mg of rivaroxaban. The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced by baseline chronic kidney disease (CKD) status (as a proxy for measured baseline renal function).
Conditions Studied
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
Study Locations (1)
New York
- - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,507 participants |
| Start Date | 2016-02-12 |
| Est. Completion | 2016-03-01 |
What the finished NCT03242278 record still lists
NCT03242278 is an observational study that tracks outcomes without assigning an intervention. Its 12,507 participants enrollment target places it among the larger protocols in the corpus, above the 2,935-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (326% higher).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Rivaroxaban (Xarelto, BAY59-7939) is the first listed.
NCT03242278 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03242278 about?
NCT03242278 is a clinical study titled "Real-world Dosing Patterns of Rivaroxaban in the United States". The primary objective is to assess the proportion of Non-valvular atrial fibrillation (NVAF) patients receiving the standard dose of 20 mg of rivaroxaban or the reduced dose of 15 mg of rivaroxaban. The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced by base...
What is the current status of trial NCT03242278?
This trial is currently completed. The enrollment target is 12,507 participants. The study started on 2016-02-12. Estimated completion is 2016-03-01.
What conditions does trial NCT03242278 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT03242278?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939) (DRUG).
Who is sponsoring clinical trial NCT03242278?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03242278 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03242278's enrollment target sits among peer trials
12,507 11th of 202 higher than 192 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04888832 · 12,500 participants · NA
The Effect of Work Requirements in SNAP in Virginia
- NCT05452941 · 12,500 participants
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
- NCT07069556 · 12,500 participants
ColoSense Post-Approval Study
- NCT07037433 · 12,800 participants · Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI